Discovery, Selection, and Development of Drug Candidates: A Senior Leadership Perspective

[custom_field limit=”0″ between=”, ” /]

Friday, November 17, 2006

Location
Somerset Marriott
110 Davidson Avenue
Somerset, New Jersey 08873

Drs. Paul Feldman, Malcolm MacCoss, Bruce Roth, Carl Decicco, and 2006 OTG Committee

Invited Speakers

• Dr. P. Roy Vagelos (Retired Chairman and CEO, Merck & Co., Inc.)
  “The Changing Pharmaceutical Industry”
• Dr. Carl Decicco (Bristol-Myers Squibb)
  “Innovation in Drug Discovery”
• Dr. Paul Feldman (GlaxoSmithKline)
  “PPAR Pan Agonists-The Next Generation PPAR Ligands”
• Dr. Malcolm MacCoss (Merck)
  “EMEND(c) (Aprepitant) a potent, orally active Substance P Antagonist for the treatment of Chemotherapy Induced Nausea and Vomiting (CINV), from the medicinal chemistry bench to the clinic”
• Dr. Bruce Roth (Pfizer)
  “The Discovery and Development of Lipitor”